You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Bedside Relational Agent to Improve Hematopoietic Cell Transplantation Outcomes in Cancer Patients

    SBC: CARE.COACH CORPORATION            Topic: 101

    Abstract Deliriuma major cause of fallscan occur in as many asof cancer patients undergoing stem cell transplantationresulting in up totimes greater chance of dyingDelirium risk can be mitigated and many other outcomes of stem cell transplants can be improved through behavioral interventions delivered at the bedside through conversationimageryand audioHowevertraditional means of delivering these i ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. A Better Mechanism for Controlled Nanopore Translocation

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: 172

    Project Summary Enabling high accuracy nanopore based strand sequencing has the potential to improve the understanding of long range genomic relationships and processes andbased on its accessibilityenable the associated clinical and diagnostic applicationsthe fastest growing sequencing sectorUnfortunatelyit is commonplace for nanopore sequencing error rates to exceedand higher accuracy is needed t ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Accurate and efficient density functional theory calculations of intermolecular interactions and conformational energies

    SBC: Q-CHEM INC            Topic: 300

    Abstract Biophysical properties can be computer-modeled using quantum mechanics (QM). While vastly more computationally costly than molecular mechanics (MM), QM methods are essential for bond-breaking and/or high accuracy. Indeed, QM methods have advanced with exciting, (and ongoing) improvements in the accuracy of density functional theory (DFT). These DFT improvements could open new applications ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease

    SBC: IMMUNOGENICS LLC            Topic: NIAID

    Project Summary AbstractThe goal of this work is to develop a therapeutic drug that will protect individuals with celiac diseaseCDfrom intestinal and symptomatic distress they suffer due to minute ingestion of gluten proteinCD is an autoimmune disorder affecting the small intestineafflicting aboutof the world s populationfor which there is no known cureCurrently the only therapeutic option to avoi ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease

    SBC: IMMUNOGENICS LLC            Topic: 300

    Project Summary The goal of this work is to evaluate the efficacy of a therapeutic agent for protecting individuals with TypediabetesT Dand celiac diseaseCDfrom intestinal and symptomatic distress they suffer due to minute ingestion of gluten proteinBoth T D and CD are lifelong autoimmune diseases whose management is anchored upon very restrictive and distinct dietsThe co morbidity of these two di ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A Comprehensive Fall Prevention System for Memory Care: Final Feasibility and Randomized Controlled Study

    SBC: SAFELYYOU INC.            Topic: NIA

    Abstract In the US, Alzheimer’s disease (AD) is the single most expensive disease, the only disease in the top six for which the number of deaths is increasing. The greatest cost contributors are frequent hospitalizations, where falls are the largest culprit, and frequent need for assistance with the activities of daily living. Fall safety systems show the potential to reduce costs and increase ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma

    SBC: Avenzoar Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Advanced Production of High Purity Radioisotopes for Nuclear Medicine

    SBC: Purist Inc            Topic: 400

    Project Summary Abstract ! The availability of reactor produced radioisotopes relies significantly on aging foreign resourcesleading to an uncertainty in the future supply of these lifesaving radioactive ingredientsThe long term goal of this effort is development of a platform technology that can be implemented in existing research reactor infrastructure nationwide for local medical grade radioiso ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic

    SBC: Riboscience LLC            Topic: NIDA

    Our goal is to develop an ultra short curative regimen for hepatitis C virus (HCV) infection in OUD patients. HCV is a major co-morbidity of many OUD patients. Treating their HCV reduces their subsequent IV drug use. While currently available regimens can cure HCV in most patients in 8-12 weeks, longer in patients with advanced liver disease or drug resistance mutations that are more frequent in O ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database

    SBC: PROTABIT, LLC            Topic: 400

    PROJECT SUMMARY Therapeutic antibodies, specialized enzymes for drug manufacturing, small molecule drug screening agents, and other proteins have been instrumental in advancing biotechnology and medicine. Protein therapeutics alone represents a rapidly growing $100+ billion market with broad applications in the treatment of cancer, inflammatory and metabolic diseases, and numerous other disorders. ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government